Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avivagen Inc VIVXF

Avivagen Inc. is a Canada-based life sciences company. The Company is focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance. The Company’s operations as one segment, products based on OxC-beta Technology. It OxC-beta technology is derived from its discoveries about B-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colors. OxC- beta Livestock is a proprietary product, an alternative to the antibiotics commonly added to livestock feeds. The product is available for sale in the United States, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia. It offers OxC-beta to approximately 46.6 million food animals (poultry, swine, and dairy cattle), 133,820 dogs and 4,000 people.


GREY:VIVXF - Post by User

Bullboard Posts
Comment by smallcaploveron Feb 21, 2013 2:50pm
208 Views
Post# 21024278

RE: RE: RE: RE: RE: RE: The bid

RE: RE: RE: RE: RE: RE: The bid

The update didn't say much, it was mostly backward-looking, but I've already commented on that.  What will drive this company through 2013 will be 1. announcements on the feed side, 2. publication of the scientific studies that will allow for the scientific community to get on board, making way for the less-technical to also get on board, and 3. distribution agreements on the companion animal side.  The latter becomes less important as the first starts to gain traction.  It will still get the company cash flow positive sooner, but the gravy is in the feed side of the business.  Ultimately, I agree with the 60-70 cent target.  I'd say December 2013 for that, but it's just a guess.  I'll be patient for the 8-bagger.  Hey, we're already up 70% from the summer when we were buying....

 

Bullboard Posts